Navigation Links
Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial
Date:11/4/2008

ing statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the tolerability of REOLYSIN(R) outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Clinical Update Conference Call
2. Oncolytics Biotech Inc. Collaborators Present Positive Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting
3. Oncolytics Biotech Inc. Collaborators Present Positive Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting
4. Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting
5. Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting
6. Oncolytics Biotech Inc. Collaborators Present Reovirus and Melanoma Research at EORTC-NCI-AACR Symposium
7. Oncolytics Biotech Inc. Collaborators to Present Preclinical Combination REOLYSIN(R) and Cisplatin Research at EORTC-NCI-AACR Annual Meeting
8. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2008
9. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
10. Oncolytics Biotech Inc. Completes Initial Scale Up of Manufacturing Process for REOLYSIN(R) to Commercial Scale
11. Media Advisory - Oncolytics Biotech Inc. to Present at Maxim Group Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Shimadzu Scientific Instruments introduces ... which offers a powerful separation method for ... provides a new level of knowledge and ... to scientists analyzing pharmaceutical impurities, proteins, lipids, ... Comprehensive 2D-LC combines two independent separation modes ...
(Date:9/17/2014)... PA & Rockville, MD (PRWEB) September 17, 2014 ... won a Small Business Innovation Research (SBIR) grant to ... immunotherapy. The award will provide ITI with approximately $255,000 ... Tree nuts, a leading cause of food allergy, affect ... cause of anaphylaxis behind peanut allergy. Tree nut exposure ...
(Date:9/17/2014)... , Sept. 17, 2014 /PRNewswire/ - SQI Diagnostics ... that develops and commercializes proprietary technologies and products for ... have been approved for trading in the ... Trading is expected to commence on September 17, 2014 ... will continue to trade on the TSX Venture Exchange ...
(Date:9/17/2014)... Escape Alert, LLC . filed international patents ... alert owners if their pet has escaped and enable them to ... in the pet’s body. This is the first implantable microchip ... been around for many years, they are passive until read by ... a pet’s location or alert the owner that the pet has ...
Breaking Biology Technology:Shimadzu’s New Nexera-e Two Dimensional Comprehensive Liquid Chromatograph Empowers Laboratories to Separate Even the Most Complex Mixtures 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3Implantable Microchip for Pets with GPS Tracking - Patent Filed by Escape Alert, LLC. 2Implantable Microchip for Pets with GPS Tracking - Patent Filed by Escape Alert, LLC. 3
... train workforce, stimulate economy ALEXANDRIA, Va., May 7 ... budget request, proposing level funding for the Carl D. ... $1.3 billion. The Perkins Act is the primary source ... connect education and real-world careers. The Association for Career ...
... May 7 Elsevier,one of the world,s leading ... and services, announced today that Michael Hansen,CEO of ... in,light of recent allegations of improper Australia based ... "Elsevier prides itself on ...
... 7 The Sixth Annual Healthcare Unbound Conference & ... will feature the coming together of consumer and healthcare ... The Conference will take place at the Seattle ... Attendees will include a diverse representation of the ...
Cached Biology Technology:Obama Budget Level Funds Career Technical Education 2Obama Budget Level Funds Career Technical Education 3Statement From Michael Hansen, CEO of Elsevier's Health Sciences Division, Regarding Australia Based Sponsored Journal Practices Between 2000 and 2005 2Sixth Annual Healthcare Unbound Conference to Focus on Remote Monitoring, Home Telehealth & eHealth for Chronic Care Management & Wellness Promotion 2Sixth Annual Healthcare Unbound Conference to Focus on Remote Monitoring, Home Telehealth & eHealth for Chronic Care Management & Wellness Promotion 3
(Date:9/17/2014)... crime unit designed to fight food fraud in ... being passed off as beef scientists from Germany ... describe their approach, which represents a vast improvement over ... Food Chemistry . , Hans-Ulrich Humpf and colleagues note ... But they also say that adding, for example, horse ...
(Date:9/16/2014)... of severe maternal morbidity amongst women in Australia ... new study published today (17 September) in ... . , Australians generally enjoy high standards of ... disparities exist, in particular between indigenous and non ... explore the independent impact of socioeconomic position on ...
(Date:9/16/2014)... The 36 Pit Fire began on September 13, 2014. ... It is currently over 2,300 acres in size and ... The 36 Pit Fire was calm Monday night due to ... establishing an anchor point and beginning to construct a fireline ... The following resources are working on the fire: , 7 ...
Breaking Biology News(10 mins):New study examines the impact of socioeconomic position & maternal morbidity in Australia 2New study examines the impact of socioeconomic position & maternal morbidity in Australia 3
... at levels consumed by breast cancer patients and survivors in ... rats, new research found., The role of folate, a ... development and progression of breast cancer is highly controversial. ... breast cancer, recent studies have suggested that taking high amounts ...
... When the temperature rises on Baffin Island, in the ... ice for thousands of years, are exposed. Using radiocarbon ... has calculated the age of relic moss samples that ... moss samples would have been destroyed by erosion had ...
... the Montreal Neurological Institute and Hospital in Canada ... Parkinson,s disease are involved in the early-stage quality ... reported in T he EMBO Journal , removes ... mitochondria., "PINK1 and parkin, are implicated in selectively ...
Cached Biology News:Large amounts of folic acid shown to promote growth of breast cancer in rats 2Quality control of mitochondria as a defense against disease 2
Mouse monoclonal [6G11] to Cytohesin 1 + 2 ( Abpromise for all tested applications)....
HNF-1 Purified Anti-Mouse, Anti-Rat, Anti-Rabbit, Anti-Human clone 2, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
Recombinant Porcine IL-1 alpha/IL-1F1, CF...
... siSolutions siRNA Custom Synthesis ... effective duplex RNA to knockdown ... 21-mers (19 RNA base pairs ... recently-published 27-mers, or other lengths ...
Biology Products: